On April 7, 2023, Kronos Bio, Inc. appointed Katherine Vega Stultz to Board of Directors (the Board) as a Class II director with a term ending at annual meeting of stockholders to be held in 2025. Ms. Stultz's appointment to the Board became effective on April 10, 2023. On May 26, 2023, Ms. Stultz was appointed as a member of the Audit Committee and of the Compensation Committee of the Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9995 USD | -2.01% | -4.81% | -20.04% |
09/05 | Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M | MT |
09/05 | Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.04% | 6.13Cr | |
+29.03% | 4.82TCr | |
-0.10% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+11.48% | 2.56TCr | |
-22.74% | 1.9TCr | |
+9.06% | 1.29TCr | |
+30.01% | 1.2TCr | |
-1.51% | 1.18TCr |
- Stock Market
- Equities
- KRON Stock
- News Kronos Bio, Inc.
- Kronos Bio, Inc. Appoints Katherine Vega Stultz as Member of the Audit Committee and of the Compensation Committee of the Board